Education
About Us
Working with TipRanks
Follow Us
Phio Pharmaceuticals (PHIO)
NASDAQ:PHIO
PHIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.22 - $9.79
Previous CloseN/A
Volume62.29K
Average Volume (3M)141.68K
Market Cap
$6.23M
Enterprise Value-$1.97M
Total Cash (Recent Filing)$14.24M
Total Debt (Recent Filing)$642.00K
Price to Earnings (P/E)―
Beta2.23
Next Earnings
May 08, 2025EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.94
Shares Outstanding4,776,848
10 Day Avg. Volume99,440
30 Day Avg. Volume141,678
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.31
Enterprise Value/Ebitda0.27
Forecast
1Y Price Target
$4.00Price Target Upside207.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Phio Pharmaceuticals News
PremiumCompany Announcements
Phio Pharmaceuticals Appoints David Deming to Board
---
Ownership Overview
1.04% Insiders
0.17% Mutual Funds
0.86% Other Institutional Investors
97.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PHIO FAQ
What was Phio Pharmaceuticals’s price range in the past 12 months?
Phio Pharmaceuticals lowest stock price was $1.22 and its highest was $9.79 in the past 12 months.
What is Phio Pharmaceuticals’s market cap?
Phio Pharmaceuticals’s market cap is $6.23M.
When is Phio Pharmaceuticals’s upcoming earnings report date?
Phio Pharmaceuticals’s upcoming earnings report date is May 08, 2025 which is in 41 days.
How were Phio Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Phio Pharmaceuticals overvalued?
According to Wall Street analysts Phio Pharmaceuticals’s price is currently Undervalued.
Does Phio Pharmaceuticals pay dividends?
Phio Pharmaceuticals does not currently pay dividends.
What is Phio Pharmaceuticals’s EPS estimate?
Phio Pharmaceuticals’s EPS estimate is -1.23.
How many shares outstanding does Phio Pharmaceuticals have?
Phio Pharmaceuticals has 4,776,848 shares outstanding.
What happened to Phio Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Phio Pharmaceuticals?
Currently, no hedge funds are holding shares in PHIO
---
Company Description
Phio Pharmaceuticals
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
---
PHIO Stock 12 Month Forecast
Average Price Target
$4.00
▲(207.69% Upside)
Technical Analysis
Best Analysts Covering PHIO
1 Year
1 Year Success Rate
0/16 ratings generated profit
1 Year Average Return
-62.91%
reiterated a buy rating last month
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -62.91% per trade.
---